Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2012 Biomarkers information updated
- 06 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.